15-min delayed · Sep 4, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering LENZ Therapeutics Inc, 4 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $7.00 to $50.00 (about 7.1x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $28.80 sits 382% above the current $5.97. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 30% this year and 203% next, consensus EPS building from about $-0.93 next quarter toward $-3.08 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy480%
Hold120%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to LENZ Therapeutics Inc.
As of Sep, 4 of 5 firms rate LENZ a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LENZ EPS & revenue forecast
EPS · NEXT QUARTER
$-0.93
Range $-1.24 – $-0.64 · 6 analysts · -20% YoY
Next period, 6 analysts expect LENZ Therapeutics Inc to earn $-0.93 a share (range $-1.24 – $-0.64), versus $-1.16 a year earlier. Full-year consensus is $-4.25, growing to $-3.08 the year after.
REVENUE · NEXT QUARTER
$5.2M
Range $3.6M – $8.1M · 6 analysts · -41% YoY
Revenue is expected to reach $5.2M (range $3.6M – $8.1M), -41.0% year-over-year. Full-year consensus is $17.0M, rising to $43.0M next year.
Top analysts covering LENZ Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LENZ.
#1
MC
Matthew Caufield
HC Wainwright & Co. · Rank #92
Buy
$38.00+536.5% to target
Overall win rate
54%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #125
Buy
$31.00+419.3% to target
Overall win rate
46%
+ Follow
#3
Yigal Nochomovitz
Citigroup · Rank #245
Buy
$20.00+235.0% to target
Overall win rate
41%
+ Follow
#4
Biren Amin
Piper Sandler
Hold
$7.00+17.3% to target
Coverage
—
+ Follow
#5
LH
Lachlan Hanbury Brown
William Blair
Buy
No targeton LENZ
Coverage
—
+ Follow
LENZ stock forecast FAQ
What is LENZ's average 12-month price target?+
The 5 analysts with a live target average $28.80 for LENZ Therapeutics Inc over the next 12 months, ranging from a $50.00 high to a $7.00 low.
Is LENZ stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 4 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for LENZ?+
The Street-high target is $50.00 (Raymond James), and the Street-low is $7.00 (Piper Sandler). The average of all 5 active targets is $28.80.
How many Wall Street analysts cover LENZ?+
5 analysts have an active rating on LENZ Therapeutics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering LENZ?+
Among analysts who currently cover LENZ, Matthew Caufield of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #92). Their current call is Buy with a $38.00 target.
What is LENZ Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.93 per share (range $-1.24 – $-0.64) across 6 analysts. Full-year EPS is projected at $-4.25, rising to $-3.08 the following year.
How much revenue is LENZ Therapeutics Inc expected to report next quarter?+
Consensus revenue is $5.2M (range $3.6M – $8.1M). Full-year revenue is projected at $17.0M, growing to $43.0M next year.
Have analysts been upgrading or downgrading LENZ lately?+
As of Sep, 4 of 5 firms rate LENZ a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LENZ calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
